Since a significant increase of AKR1B10 in steatohepatitis was first found in 2012 [108], it has been confirmed in biopsy samples and sera from NAFLD patients [109,110,111,112,113,114,115,116], indicating that AKR1B10 is a consistent marker for the progression of NAFLD/NASH. This evidence concerns the gene AKR1B10 and metabolic dysfunction-associated steatohepatitis.